• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Abbott Laboratories (ABT) Could Be 6% Below Fair Value Following Libre Duo FDA Approval

    Simply Wall St·08/30/2026 06:22:55
    Listen to the news

    Why the Libre Duo 10 Day approval matters for Abbott Laboratories stock

    Abbott Laboratories (ABT) drew fresh attention after the FDA authorized its Libre Duo 10 Day dual glucose ketone sensor for people with diabetes, a milestone that broadens the company’s diabetes technology footprint.

    The system is designed to continuously track glucose and ketone levels, with alerts for rising ketones that may signal risk of diabetic ketoacidosis. Investors now have a new product to watch as Abbott prepares a United States launch later this year and pursues integration with automated insulin delivery partners.

    For context, Abbott Laboratories shares closed at US$112.47, with a 90 day share price return of 28.13% and a 30 day share price return of 6.40%. The year to date share price return is down 9.44% and the 1 year total shareholder return is down 13.26%, pointing to recent momentum rebuilding after a weaker spell for longer term holders.

    Spot opportunities around Abbott Laboratories by scanning a hand picked group of resilient healthcare and medtech companies in the 75 resilient stocks with low risk scores.

    After a sharp 90 day rebound and fresh attention on Libre Duo 10 Day, Abbott Laboratories now faces a simple test. Does the current valuation still leave enough upside to justify the risks that come with it?

    Most Popular Narrative: 5.6% Undervalued

    At a last close of $112.47 against a narrative fair value of $119.13, Abbott Laboratories is framed as modestly undervalued, with Libre Duo 10 Day feeding into a broader multi year growth story.

    Abbott's ongoing innovation in high-margin segments, most notably through the FreeStyle Libre franchise (with next-gen, dual-analyte sensors and new software integrations) and pipeline launches in structural heart and rhythm management devices, positions the company to capture incremental market share and drive net margin expansion.

    Read the complete narrative. Read the complete narrative.

    Want to see what underpins that fair value gap for Abbott Laboratories? The narrative focuses on assumptions related to revenue trends, margins, and future earnings multiples. The exact mix of those assumptions might surprise you. The full breakdown shows how each piece feeds into that $119.13 figure.

    Result: Fair Value of $119.13 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, investors in Abbott Laboratories still need to watch for pressure on diagnostic pricing in China and any future litigation or regulatory setbacks that could unsettle sentiment.

    Find out about the key risks to this Abbott Laboratories narrative.

    Next Steps

    With mixed signals around risks and rewards for Abbott Laboratories, it can be useful to move quickly and test the narrative against the numbers yourself. You can weigh both sides of the story in one place by reviewing the 3 key rewards and 2 important warning signs.

    Looking for more investment ideas beyond Abbott Laboratories?

    If you stop with Abbott Laboratories, you risk missing other stocks that could suit your goals. Take a few minutes to scan fresh ideas tailored to different approaches.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.